Resources from the same session
LBA17 - Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial
Presenter: Oleg Gluz
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
239MO - TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial
Presenter: Maria Vittoria Dieci
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA15, LBA16, LBA17 and 239MO
Presenter: Fatima Cardoso
Session: Mini oral session: Breast cancer, early stage
Resources:
Slides
Webcast